Literature DB >> 10690522

Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.

B Powell1, R Soong, B Iacopetta, R Seshadri, D R Smith.   

Abstract

Alteration to the p53 tumor suppressor gene is associated with more aggressive disease in breast cancer, as evidenced by the shortened survival of patients with mutation. Data obtained from in vitro experiments suggest that mutations to different structural and functional domains of p53 may give rise to different effects on its biological activities, notably transactivational and apoptotic properties. We evaluated the prognostic significance of various types of p53 mutation in a series of 178 tumors identified by PCR-single-strand conformational polymorphism screening as containing a mutant gene. Mutations within exon 4 were associated with particularly poor prognosis, possibly relating to the importance of this region in apoptosis. Mutations that caused denaturation of the protein structure were also associated with poor survival, again perhaps because of effects on apoptosis. In contrast, patients with mutations in the DNA contact region showed similar survival to that of patients with normal p53, suggesting a less important role for p53-mediated transactivation in determining tumor aggressiveness. Other mutation groups associated with poor prognosis were single-base substitutions and transversion mutations. Mutations in exon 6, exon 7, or the "hotspot" codons (175, 245, 248, 273) were associated with only a small reduction in patient survival compared with normal p53. These results allow some insight to be gained into the functional importance of various p53 domains in terms of their influence on overall patient survival. Further work is required to determine whether these domains are also important in influencing the response of breast tumors to adjuvant therapies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10690522

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

1.  Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.

Authors:  Jie Xu; Joke Reumers; José R Couceiro; Frederik De Smet; Rodrigo Gallardo; Stanislav Rudyak; Ann Cornelis; Jef Rozenski; Aleksandra Zwolinska; Jean-Christophe Marine; Diether Lambrechts; Young-Ah Suh; Frederic Rousseau; Joost Schymkowitz
Journal:  Nat Chem Biol       Date:  2011-03-27       Impact factor: 15.040

2.  Clinicopathologic characteristics of brain tumors are associated with the presence and patterns of TP53 mutations: evidence from the IARC TP53 Database.

Authors:  Lyubov E Salnikova
Journal:  Neuromolecular Med       Date:  2014-01-31       Impact factor: 3.843

Review 3.  Integrated gene networks in breast cancer development.

Authors:  Ivana Ratkaj; Emil Stajduhar; Srdan Vucinic; Sime Spaventi; Hrvojka Bosnjak; Kresimir Pavelic; Sandra Kraljevic Pavelic
Journal:  Funct Integr Genomics       Date:  2010-02-04       Impact factor: 3.410

4.  AIMP2/p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53.

Authors:  Jung Min Han; Bum-Joon Park; Sang Gyu Park; Young Sun Oh; So Jung Choi; Sang Won Lee; Soon-Kyung Hwang; Seung-Hee Chang; Myung-Haing Cho; Sunghoon Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-11       Impact factor: 11.205

5.  Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution.

Authors:  Wenjing Zhou; Aslaug A Muggerud; Phuong Vu; Eldri U Due; Therese Sørlie; Anne-Lise Børresen-Dale; Fredrik Wärnberg; Anita Langerød
Journal:  Mol Oncol       Date:  2009-04-02       Impact factor: 6.603

6.  Predicting survival in head and neck squamous cell carcinoma from TP53 mutation.

Authors:  David L Masica; Shuli Li; Christopher Douville; Judith Manola; Robert L Ferris; Barbara Burtness; Arlene A Forastiere; Wayne M Koch; Christine H Chung; Rachel Karchin
Journal:  Hum Genet       Date:  2014-08-10       Impact factor: 4.132

7.  Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma.

Authors:  Venkat R Katkoori; Xu Jia; Chandrakumar Shanmugam; Wen Wan; Sreelatha Meleth; Harvey Bumpers; William E Grizzle; Upender Manne
Journal:  Clin Cancer Res       Date:  2009-04-01       Impact factor: 12.531

8.  Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.

Authors:  Lynnette Fernández-Cuesta; Catherine Oakman; Priscila Falagan-Lotsch; Ke-Seay Smoth; Emmanuel Quinaux; Marc Buyse; M Stella Dolci; Evandro De Azambuja; Pierre Hainaut; Patrizia Dell'orto; Denis Larsimont; Prudence A Francis; John Crown; Martine Piccart-Gebhart; Giuseppe Viale; Angelo Di Leo; Magali Olivier
Journal:  Breast Cancer Res       Date:  2012-05-02       Impact factor: 6.466

9.  Mutations in p53, p53 protein overexpression and breast cancer survival.

Authors:  Pavel Rossner; Marilie D Gammon; Yu-Jing Zhang; Mary Beth Terry; Hanina Hibshoosh; Lorenzo Memeo; Mahesh Mansukhani; Chang-Min Long; Gail Garbowski; Meenakshi Agrawal; Tara S Kalra; Mia M Gaudet; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella
Journal:  J Cell Mol Med       Date:  2008-10-16       Impact factor: 5.310

10.  Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma.

Authors:  Frédérique Végran; Magali Rebucci; Sandy Chevrier; Muriel Cadouot; Romain Boidot; Sarab Lizard-Nacol
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.